Skip to content
DataLookout
Menu

NCT06058442

The Pancreatic Enzymes After Gastrectomy Trial

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 21 words
    • Trial sites expanded: 12 → 15 locations
    • Secondary endpoints: details revised at 1 of 13 entries
  2. Notable Primary and study completion pushed from Jun 2027 to Feb 2028
    • Eligibility criteria expanded, about 1 word
    • Trial sites expanded: 9 → 12 locations
    v7
  3. Notable Primary and study completion dates: Apr 2026 to Jun 2027
    • Eligibility criteria expanded, about 11 words
    • Study sites: 7 to 9
    v6
  4. Minor Study sites: 6 to 7v5
  5. Minor Study sites: 4 to 6v4
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Secondary endpoints: details revised at 11 of 13 entriesv3
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 4
    • Start date changed from estimate of Oct 2023 to Jan 24, 2024
    • Secondary endpoints revised (13)
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Disease specific quality of life (QOL)
Timeframe: 6 months

Secondary (13)

Nutritional supplementation or weight loss
Weight
Serum haemoglobin
Total protein
Albumin
Show 8 moreShow less
Glucose
HbA1c
Cholesterol
Vitamin A
Vitamin B12
Vitamin D
Vitamin E
Vitamin K

Arms and interventions

NORTASE®Experimental
PlaceboPlacebo comparator

Drugs: NORTASE®, Placebo

Sites

15 sites in 1 country